Ripretinib-Induced Focal Segmental Glomerulosclerosis in a Patient With Gastrointestinal Stromal Tumor (GIST)

Key Points

• Focal segmental glomerulosclerosis developed following treatment with ripretinib, indicating a potential adverse effect.
• The patient experienced notable renal impairment, emphasizing the need for monitoring kidney function during treatment.
• Observational analysis explored the link between ripretinib and renal pathology in a GIST patient, shedding light on treatment implications.
• Further investigations are required to understand the mechanisms behind ripretinib-induced renal issues, including adverse events.